Filing Details
- Accession Number:
- 0000899243-19-001662
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-01-22 20:44:48
- Reporting Period:
- 2019-01-18
- Accepted Time:
- 2019-01-22 20:44:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1626199 | Alpine Immune Sciences Inc. | ALPN | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1242882 | Mitchell Gold | C/O Alpine Immune Sciences, Inc. 201 Elliott Avenue West, Suite 230 Seattle WA 98119 | Executive Chairman And Ceo | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-01-18 | 190,875 | $5.37 | 3,994,781 | No | 4 | P | Indirect | Alpine ImmunoSciences, L.P. |
Common Stock | Disposition | 2018-05-14 | 3,000 | $0.00 | 20,292 | No | 5 | G | Direct | |
Common Stock | Disposition | 2018-05-15 | 3,000 | $0.00 | 17,292 | No | 5 | G | Direct | |
Common Stock | Disposition | 2018-05-21 | 6,000 | $0.00 | 11,292 | No | 5 | G | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | Alpine ImmunoSciences, L.P. |
No | 5 | G | Direct | |
No | 5 | G | Direct | |
No | 5 | G | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrant (right to buy) | Acquisiton | 2019-01-18 | 74,441 | $0.00 | 74,441 | $12.74 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
74,441 | 2019-01-18 | 2024-01-18 | No | 4 | P | Indirect |
Footnotes
- Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock.
- Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
- The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.